Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-alpha treatment
Happonen, Kaisa LU ; Saxne, Tore LU ; Geborek, Pierre LU ; Andersson, Maria ; Bengtsson, Anders LU ; Hesselstrand, Roger LU ; Heinegård, Dick LU and Blom, Anna LU
(2012)
In Arthritis Research and Therapy
14(1).
- Abstract
- Introduction: Cartilage oligomeric matrix protein (COMP) is found at elevated concentrations in sera of patients with joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). We recently showed that COMP activates complement via the alternative pathway and that COMP-C3b complexes are present in sera of RA patients, but not in healthy controls. We now set out to elaborate on the information provided by this marker in a variety of diseases and larger patient cohorts. Methods: COMP-C3b levels in sera were measured by using an enzyme-linked immunosorbent assay (ELISA) capturing COMP and detecting C3b. Serum COMP was measured by using ELISA. Results: COMP-C3b levels were significantly elevated in patients with RA as well as in... (More)
- Introduction: Cartilage oligomeric matrix protein (COMP) is found at elevated concentrations in sera of patients with joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). We recently showed that COMP activates complement via the alternative pathway and that COMP-C3b complexes are present in sera of RA patients, but not in healthy controls. We now set out to elaborate on the information provided by this marker in a variety of diseases and larger patient cohorts. Methods: COMP-C3b levels in sera were measured by using an enzyme-linked immunosorbent assay (ELISA) capturing COMP and detecting C3b. Serum COMP was measured by using ELISA. Results: COMP-C3b levels were significantly elevated in patients with RA as well as in systemic lupus erythematosus (SLE), compared with healthy controls. SLE patients with arthritis had significantly higher COMP-C3b levels than did those without. COMP-C3b was furthermore elevated in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis, systemic sclerosis, and OA. COMP-C3b did not correlate with COMP in any of the patient groups. COMP-C3b correlated with disease activity in RA, but not in other diseases. COMP-C3b levels in RA patients decreased on treatment with tumor necrosis factor (TNF)-alpha inhibitors, whereas the levels increased in patients with AS or PsA. The changes of COMP-C3b did not parallel the changes of C-reactive protein (CRP). Conclusions: COMP-C3b levels are elevated in several rheumatologic diseases and correlate with inflammatory measures in RA. COMP-C3b levels in RA decrease during TNF-alpha inhibition differently from those of CRP, suggesting that formation of COMP-C3b relates to disease features not reflected by general inflammation measures. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2906366
- author
- Happonen, Kaisa
LU
; Saxne, Tore
LU
; Geborek, Pierre
LU
; Andersson, Maria
; Bengtsson, Anders
LU
; Hesselstrand, Roger
LU
; Heinegård, Dick
LU
and Blom, Anna
LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Arthritis Research and Therapy
- volume
- 14
- issue
- 1
- article number
- R15
- publisher
- BioMed Central (BMC)
- external identifiers
-
- wos:000304698800029
- scopus:84856022022
- pmid:22264230
- ISSN
- 1478-6362
- DOI
- 10.1186/ar3694
- language
- English
- LU publication?
- yes
- id
- 8e22eab2-b576-44f1-9cbf-3ea1c0ca6395 (old id 2906366)
- date added to LUP
- 2016-04-01 11:17:23
- date last changed
- 2022-05-14 00:38:12
@article{8e22eab2-b576-44f1-9cbf-3ea1c0ca6395,
abstract = {{Introduction: Cartilage oligomeric matrix protein (COMP) is found at elevated concentrations in sera of patients with joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). We recently showed that COMP activates complement via the alternative pathway and that COMP-C3b complexes are present in sera of RA patients, but not in healthy controls. We now set out to elaborate on the information provided by this marker in a variety of diseases and larger patient cohorts. Methods: COMP-C3b levels in sera were measured by using an enzyme-linked immunosorbent assay (ELISA) capturing COMP and detecting C3b. Serum COMP was measured by using ELISA. Results: COMP-C3b levels were significantly elevated in patients with RA as well as in systemic lupus erythematosus (SLE), compared with healthy controls. SLE patients with arthritis had significantly higher COMP-C3b levels than did those without. COMP-C3b was furthermore elevated in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis, systemic sclerosis, and OA. COMP-C3b did not correlate with COMP in any of the patient groups. COMP-C3b correlated with disease activity in RA, but not in other diseases. COMP-C3b levels in RA patients decreased on treatment with tumor necrosis factor (TNF)-alpha inhibitors, whereas the levels increased in patients with AS or PsA. The changes of COMP-C3b did not parallel the changes of C-reactive protein (CRP). Conclusions: COMP-C3b levels are elevated in several rheumatologic diseases and correlate with inflammatory measures in RA. COMP-C3b levels in RA decrease during TNF-alpha inhibition differently from those of CRP, suggesting that formation of COMP-C3b relates to disease features not reflected by general inflammation measures.}},
author = {{Happonen, Kaisa and Saxne, Tore and Geborek, Pierre and Andersson, Maria and Bengtsson, Anders and Hesselstrand, Roger and Heinegård, Dick and Blom, Anna}},
issn = {{1478-6362}},
language = {{eng}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{Arthritis Research and Therapy}},
title = {{Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-alpha treatment}},
url = {{https://lup.lub.lu.se/search/files/2534784/3460591.pdf}},
doi = {{10.1186/ar3694}},
volume = {{14}},
year = {{2012}},
}